Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 701–800 of 1,012
AHTN and HHCB show weak estrogenic — but no uterotrophic activity
Seinen, W., Lemmen, J. G., Pieters, R. H. H., Verbruggen, E. M. J., & van der Burg, B. (1999) · Toxicology Letters · doi:10.1016/s0378-4274(99)00177-0 · Cited by 107
Furukawa, T., Bai, C., Kaihara, A., Ozaki, E., Kawano, T., Nakaya, Y., Awais, M., Sato, M., Umezawa, Y., & Kurokawa, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028134 · Cited by 107
“A structural basis of ER /coactivator recognition is well documented from the analysis of the crystal structure of ER - LBD bound to both an agonist diethylstilbestrol and a coactivator GRIP1 (Brzozowski et al., 1997; Shiau et al., 1998).”
BackgroundInfluentialAkingbemi, B. T., Ge, R., Klinefelter, G. R., Gunsalus, G. L., & Hardy, M. P. (2000) · Biology of Reproduction · doi:10.1095/biolreprod62.3.571 · Cited by 107
White, I. N. H. (1999) · Carcinogenesis · doi:10.1093/carcin/20.7.1153 · Cited by 107
Furness, S. G. B., Lees, M. J., & Whitelaw, M. L. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.04.011 · Cited by 95
“In the case of the ER, different structures can recruit activator or co-repressor complexes [70].”
BackgroundMolecular basis for gene-specific transactivation by nuclear receptors
Aagaard, M. M., Siersbæk, R., & Mandrup, S. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.018 · Cited by 108
Salste, L., Leskinen, P., Virta, M., & Krönberg, L. (2007) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2007.02.030 · Cited by 106
Ren, X., Guo, L., Gao, Y., Zhang, B., & Wan, B. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.01.026 · Cited by 106
“Structural analysis of TR/ T3 complex has demonstrated that the position of C-terminal helix 12 plays an important role in the process of coactivator recruitment (Brzozowski et al., 1997).”
Structural requirements of para‐alkylphenols to bind to estrogen receptor
Tabira, Y., Nakai, M., Asai, D., Yakabe, Y., Tahara, Y., Shinmyozu, T., Noguchi, M., Takatsuki, M., & Shimohigashi, Y. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00422.x · Cited by 106
“The three-dimensional structure of the ligand-binding domain of estrogen receptor in complex with 17b-estradiol was clarified recently by X-ray crystallographic analysis [15].”
BackgroundInfluentialL-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ
Elbrecht, A., Chen, Y., Adams, A., Berger, J., Griffin, P., Klatt, T., Zhang, B., Menke, J., Zhou, G., Smith, R. G., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7913 · Cited by 102
Therapeutic potential of selective estrogen receptor modulators
Gustafsson, J.-Α. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80127-0 · Cited by 105
Self-citationDPPH Radical-Scavenging Compounds from Dou-Chi, a Soybean Fermented Food
Chen, Y., Sugiyama, Y., Abe, N., Kuruto-Niwa, R., Nozawa, R. T., & Hirota, A. (2005) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.69.999 · Cited by 104
Fatty Acids Derived from Royal Jelly Are Modulators of Estrogen Receptor Functions
Moutsatsou, P., Papoutsi, Z., Kassi, E. N., Heldring, N., Zhao, C., Tsiapara, A., Melliou, E., Chrousos, G. P., Chinou, İ., Karshikoff, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015594 · Cited by 106
“The X-ray structure of the ERa receptor with PDB entry code 1GWR [29,30] was used in the calculations.”
BackgroundMethodRenaud, J., Bischoff, S. F., Buhl, T., Floersheim, P., Fournier, B., Halleux, C., Kallen, J., Keller, H., Schlaeppi, J.-M., & Stark, W. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030086h · Cited by 88
Bolli, A., Galluzzo, P., Ascenzi, P., Pozzo, G. D., Manco, I., Vietri, M. T., Mita, L., Altucci, L., Mita, D. G., & Marino, M. (2008) · IUBMB Life · doi:10.1002/iub.130 · Cited by 104
Regulation of protein activity with small‐molecule‐controlled inteins
Σκρέτας, Γ., & Wood, D. W. (2005) · Protein Science · doi:10.1110/ps.04996905 · Cited by 105
“The specific role of these mutations is currently under investigation but the ones found in the ligand-binding domain appear to be clustered in areas either important for hormone binding (Wrenn and Katzenellenbogen 1993; Ekena et al. 1996; Brzozowski et al. 1997) or in the vicinity of the contact points between the bi…”
BackgroundMiyagawa, S., Lange, A., Hirakawa, I., Tohyama, S., Ogino, Y., Mizutani, T., Kagami, Y., Kusano, T., Ihara, M., Tanaka, H., et al. (2014) · Environmental Science & Technology · doi:10.1021/es5002659 · Cited by 103
SRC-3/AIB1: transcriptional coactivator in oncogenesis1
Yan, J., Tsai, S. Y., & Tsai, M. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00315.x · Cited by 103
Lee, C., Chang, Y.-C., Chen, C.-S., Tu, S., Wang, Y., Chen, L.-C., Chang, Y., Wei, P., Chang, H.-W., Chang, C.-H., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1209-0 · Cited by 103
“This ER/coactivator complex activates DNA transcription by stimulating E2-responsive elements [23].”
Backgroundvan Lipzig, M. M. H., Vermeulen, N. P. E., Gusinu, R., Legler, J., Frank, H., Seidel, A., & Meerman, J. H. N. (2004) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2004.03.010 · Cited by 103
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.
Wong, M., Guo, C. H., & Zhang, J. (2014) · PubMed Central · Cited by 104
Liu, J. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.355 · Cited by 99
Pavao, M., & Traish, A. M. (2001) · Steroids · doi:10.1016/s0039-128x(00)00143-4 · Cited by 103
A Negative Coregulator for the Human ER
Norris, J. D. (2002) · Molecular Endocrinology · doi:10.1210/me.16.3.459 · Cited by 89
“several -helices within this domain (13).”
Cloning, Sequencing, and Localization of Bovine Estrogen Receptor-β within the Ovarian Follicle1
Rosenfeld, C. S., Yuan, X., Manikkam, M., Calder, M. D., Garverick, H. A., & Lubahn, D. B. (1999) · Biology of Reproduction · doi:10.1095/biolreprod60.3.691 · Cited by 103
“Additionally, within this region, dimerization between members of the nuclear receptor superfamily has been reported to occur [39, 40].”
BackgroundPotent Inhibitors of LXXLL‐Based Protein–Protein Interactions
Galande, A. K., Bramlett, K. S., Trent, J. O., Burris, T. P., Wittliff, J. L., & Spatola, A. F. (2005) · ChemBioChem · doi:10.1002/cbic.200500083 · Cited by 86
Sun, J., Baudry, J., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0341 · Cited by 91
Bentrem, D. J., Dardes, R. C., Liu, H., Schafer, J. M., Zapf, J. W., & Jordan, V. C. (2001) · Endocrinology · doi:10.1210/endo.142.2.7932 · Cited by 103
“The resolution of the x-ray crystallography of part of the ligand binding domain with E2, diethylstilbestrol, 4-OHT, and raloxifene (20, 21) demonstrates profound differences between estrogens and antiestrogens that helps to explain how antiestrogens silence activating function (AF)-2 and prevent coactivator binding.”
BackgroundMarhefka, C. A., Moore, B. M., II, Bishop, T. C., Kirkovsky, L. I., Mukherjee, A., Dalton, J. T., & Miller, D. D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0005353 · Cited by 102
Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-α
Preisler‐Mashek, M. T., Solodin, N. M., Stark, B. L., Tyriver, M. K., & Alarid, E. T. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00353.2001 · Cited by 102
“Structural studies of the ER ligand-binding domain demonstrate that tamoxifen binding disrupts the organization of critical helix 12 of ER and prevents interaction of the receptor with coactivators (6, 38).”
BackgroundEstrogen receptor cofactors expression in breast and endometrial human cancer cells
Thénot, S., Charpin, M., Bonnet, S., & Cavaillès, V. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00139-2 · Cited by 102
An intramolecular folding sensor for imaging estrogen receptor–ligand interactions
Paulmurugan, R., & Gambhir, S. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607385103 · Cited by 101
Bone targeting for the treatment of osteoporosis
Lühmann, T. C., Germershaus, O., Gröll, J., & Meinel, L. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.001 · Cited by 106
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs
Bisson, W. H., Cheltsov, A. V., Bruey-Sédano, N., Lin, B., Chen, J., Goldberger, N. E., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609752104 · Cited by 101
Hendry, L. B., Mahesh, V. B., Bransome, E. D., & Ewing, D. E. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.03.009 · Cited by 101
Jordan, V. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0029 · Cited by 102
“estrogens or antiestrogens show the potential of ligands to promote coactivator binding or prevent coactivator binding based on the shape of the estrogen or anti-ER complex (95, 96).”
BackgroundLigands specify estrogen receptor alpha nuclear localization and degradation
Kocanova, S., Mazaheri, M., Caze-Subra, S., & Bystricky, K. (2010) · BMC Cell Biology · doi:10.1186/1471-2121-11-98 · Cited by 86
“The crystal structure of ERa bound to different ligands has revealed a spectrum of conformational states [9,42-44] that involve the repositioning of helix H12 of the receptor’s ligand binding domain and formation the receptor’s cofactor associating surfaces.”
BackgroundLeclercq, G., Lacroix, M., Laïos, I., & Laurent, G. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906775471716 · Cited by 100
“This latter feature confers, upon binding, a "closed" conformation to the receptor [40].”
BackgroundInfluentialKoide, A., Zhao, C., Naganuma, M., Abrams, J., Deighton-Collins, S., Skafar, D. F., & Koide, S. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0203 · Cited by 101
“The agonist-bound LBD monomer is roughly 30 Å 40 Å 50 Å and has different surfaces involved in dimerization, ligand association and dissociation, and the binding of coregulatory proteins (39, 40).”
BackgroundKlinge, C. M., Jernigan, S. C., Smith, S. L., Tyulmenkov, V. V., & Kulakosky, P. C. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00382-3 · Cited by 100
Ligands Differentially Modulate the Protein Interactions of the Human Estrogen Receptors α and β
Margeat, E., Bourdoncle, A., Margueron, R., Poujol, N., Cavaillès, V., & Royer, C. A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01355-4 · Cited by 100
Steroid hormone receptors and dietary ligands: a selected review
Jacobs, M. N., & Lewis, D. F. V. (2002) · Proceedings of The Nutrition Society · doi:10.1079/pns2001140 · Cited by 100
Signatures of sex: Sex differences in gene expression in the vertebrate brain
Gegenhuber, B., & Tollkuhn, J. (2020) · WIREs Developmental Biology · doi:10.1002/wdev.348 · Cited by 85
“Nuclear hormone receptors are activated by hormone binding to their ligand-binding domain, which facilitates receptor dimerization, tethering to other TFs, and direct DNA binding (Brzozowski et al., 1997; Maggi, 2011).”
BackgroundPeh, W. Y. X., Reimhult, E., Teh, H. F., Thomsen, J. S., & Su, X. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.099382 · Cited by 99
“Although the structural basis of how ligands affect the recruitment of coactivators or corepressors is understood through x-ray crystallography (11,12) and NMR studies (13) on the ligand binding domain (LBD) of human estrogen receptor a (hERa), it is controversial and debatable if ligands have effects on hERa interact…”
BackgroundSusceptibility of estrogen receptor rapid responses to xenoestrogens: Physiological outcomes
Marino, M., Pellegrini, M., Rosa, P. L., & Acconcia, F. (2012) · Steroids · doi:10.1016/j.steroids.2012.02.019 · Cited by 99
Evolution of Hormone Signaling in Elasmobranchs by Exploitation of Promiscuous Receptors
Carroll, S. M., Bridgham, J. T., & Thornton, J. W. (2008) · Molecular Biology and Evolution · doi:10.1093/molbev/msn204 · Cited by 99
Ovarian steroid receptors and their role in ovarian function
Drummond, A. E., Britt, K. L., Dyson, M., Jones, M. E. E., Kerr, J. B., O’Donnell, L., Simpson, E. R., & Findlay, J. K. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00052-7 · Cited by 102
Light-Activated Gene Expression
Cruz, F. G., Koh, J. T., & Link, K. H. (2000) · Journal of the American Chemical Society · doi:10.1021/ja001804h · Cited by 99
Xue, Y., Moore, L. B., Orans, J., Peng, L., Bencharit, S., Kliewer, S. A., & Redinbo, M. R. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0323 · Cited by 93
Structural Insights into Corepressor Recognition by Antagonist-bound Estrogen Receptors
Heldring, N., Pawson, T., McDonnell, D. P., Treuter, E., Gustafsson, J.-Α., & Pike, A. C. W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611424200 · Cited by 101
Self-citationFertuck, K. C., Matthews, J. B., & Zacharewski, T. R. (2001) · Toxicological Sciences · doi:10.1093/toxsci/59.2.231 · Cited by 100
“Recent crystallization of the ligand binding domain (LBD) of both ERa and ERb in the presence of agonist or antagonist has revealed the nature of the binding pocket, which is both lined with hydrophobic amino acids and contains specific residues for hydrogen bonding with the hydroxyl groups of the ligand (Brzozowski e…”
BackgroundZhao, L., & Brinton, R. D. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-24 · Cited by 88
“The binding modes (position and orientation) of estrogens in the ligand binding site of ER were predefined by superimposing the optimized 3D structures of estrogens and the crystallographic structure of 17β-estradiol bound with its cognate receptor [58].”
MethodScobie, G. A., Macpherson, S., Millar, M. R., Groome, N. P., Romana, P. G., & Saunders, P. T. K. (2002) · Steroids · doi:10.1016/s0039-128x(02)00047-8 · Cited by 98
Matias, P. M., Carrondo, M. A., Coelho, R., Thomaz, M., Zhao, X.-Y., Wegg, A., Crusius, K., Egner, U., & Donner, P. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011072j · Cited by 86
Géhin, M., Vivat, V., Wurtz, J., Losson, R., Chambon, P., Moras, D., & Gronemeyer, H. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80084-2 · Cited by 98
Deb, P., Bhan, A., Hussain, I., Ansari, K. I., Bobzean, S. A. M., Pandita, T. K., Perrotti, L. I., & Mandal, S. S. (2016) · Gene · doi:10.1016/j.gene.2016.05.009 · Cited by 97
“Along with ERs, variety of ER-coactivators also coordinate with the estradiol-dependent gene activation and signaling (Brzozowski et al., 1997; Feng et al., 1998; Paige et al., 1999; Ansari et al., 2011b).”
BackgroundArao, Y., Hamilton, K. J., Ray, M. K., Scott, G., Mishina, Y. M., & Korach, K. S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109180108 · Cited by 97
“A portion of the AF-2 domain resides in helix 12 and plays a crucial role in determining interactions with coactivators and corepressors for transcriptional regulation influencing respective agonist or antagonist effects of the ligand (1, 2).”
BackgroundMuthyala, R. S., Sheng, S., Carlson, K. E., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204800 · Cited by 97
Dai, S. Y., Chalmers, M. J., Bruning, J. B., Bramlett, K. S., Osborne, H. E., Montrose‐Rafizadeh, C., Barr, R. J., Wang, Y., Wang, M., Burris, T. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710802105 · Cited by 97
“2B, PDB ID: 3ERT), and ER LBD/raloxifene (18) (Fig.”
BackgroundMethodTriarylpyrazoles with basic side chains
Stauffer, S. R., Huang, Y., Aron, Z. D., Coletta, C. J., Sun, J., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00226-1 · Cited by 97
Molecular Mechanism of Androgen Action
Hiipakka, R. A., & Liao, S. (1998) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00081-2 · Cited by 97
Therapeutic potential of selective modulators of nuclear receptor action
Resche-Rigon, M., & Gronemeyer, H. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80126-9 · Cited by 97
May, F. E. B. (2014) · Cancer Management and Research · doi:10.2147/cmar.s35024 · Cited by 97
Mechanisms of action of agrochemicals acting as endocrine disrupting chemicals
Warner, G. R., Mourikes, V. E., Neff, A. M., Brehm, E., & Flaws, J. A. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110680 · Cited by 96
Paris, M., Pettersson, K., Schubert, M., Bertrand, S., Pongratz, I., Escrivá, H., & Laudet, V. (2008) · BMC Evolutionary Biology · doi:10.1186/1471-2148-8-219 · Cited by 98
“This apparent absence of coactivator recruitment (see Additional file 4B) resulting in no transcriptional activity in response to BPA can be interpreted in several ways: (i) because of the different geometry of the ligand-binding pocket in amphiER, BPA behaves as an antiestrogen (partial agonist or even a partial anta…”
BackgroundLarge-scale virtual screening for discovering leads in the postgenomic era
Waszkowycz, B., Perkins, T. D., Sykes, R. A., & Li, J. (2001) · IBM Systems Journal · doi:10.1147/sj.402.0360 · Cited by 96
“(code 1ERR).(24) The crystallographic structures required minimal refinement before docking: i.”
Rsk2 allosterically activates estrogen receptor α by docking to the hormone‐binding domain
Clark, D. E., Poteet-Smith, C. E., Smith, J. A., & Lannigan, D. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3484 · Cited by 96
Egea, P. F., Rochel, N., Birck, C., Vachette, P., Timmins, P. A., & Moras, D. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4409 · Cited by 96
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.
Zilli, M., Grassadonia, A., Tinari, N., DiGiacobbe, A., Gildetti, S., Giampietro, J., Natoli, C., & Iacobelli, S. (2009) · Biochimica et Biophysica Acta · doi:10.1016/j.bbcan.2008.08.003 · Cited by 85
“binding groove [68,69], thus hampering AF2-dependent interactions with coactivators, and promotes the recruitment of corepressors [108,109].”
BackgroundAn overview on Estrogen receptors signaling and its ligands in breast cancer
Khan, M. Z. I., Uzair, M., Nazli, A., & Chen, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114658 · Cited by 98
Corepressor Recruitment by Agonist-Bound Nuclear Receptors
White, J. H., Fernandes, I., Mader, S., & Yang, X. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)68004-6 · Cited by 95
SERMs: Progress and future perspectives
Pickar, J. H., MacNeil, T., & Ohleth, K. M. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.05.009 · Cited by 96
A conserved surface on the ligand binding domain of nuclear receptors for allosteric control
Buzón, V., Carbó, L. R., Estruch, S. B., Fletterick, R. J., & Estébanez‐Perpiñá, E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.012 · Cited by 95
“However, the level of conservation of AR BF-3 with the estrogen receptor (ER) isoforms is more discrete (Brzozowski et al., 1997) (Fig.”
InfluentialMarked for Life: Epigenetic Effects of Endocrine Disrupting Chemicals
Jacobs, M. N., Marczylo, E. L., Guerrero‐Bosagna, C., & Rüegg, J. (2017) · Annual Review of Environment and Resources · doi:10.1146/annurev-environ-102016-061111 · Cited by 95
Stauffer, S. R., Huang, Y., Coletta, C. J., Tedesco, R., & Katzenellenbogen, J. A. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00228-5 · Cited by 95
Camp, H. S., Chaudhry, A., & Leff, T. (2001) · Endocrinology · doi:10.1210/endo.142.7.8254 · Cited by 87
“Conversely, antagonists block coactivator binding by disrupting the topography of the AF-2 surface, inducing a conformation that is distinct from the agonist-induced conformation (27).”
BackgroundSynthesis of potential bisphenol A substitutes by isomerising metathesis of renewable raw materials
Trita, A. S., Over, L. C., Pollini, J., Baader, S., Riegsinger, S., Meier, M. A. R., & Gooßen, L. J. (2017) · Green Chemistry · doi:10.1039/c7gc00553a · Cited by 94
Hillard, E. A., Pigeon, P., Vessières, A., Amatore, C. A., & Jaouen, G. (2007) · Dalton Transactions · doi:10.1039/b705030e · Cited by 94
p21WAF1/CIP1 Selectively Controls the Transcriptional Activity of Estrogen Receptor α
Fritah, A., Saucier, C., Mester, J., Redeuilh, G., & Sabbah, M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.6.2419-2430.2005 · Cited by 75
“The binding of the hormone to the receptor induces a conformational change in the hormone-binding domain (6).”
BackgroundJackson, A. R., Davis, J., Pither, R. J., Rodger, A., & Hannon, M. J. (2001) · Inorganic Chemistry · doi:10.1021/ic010152a · Cited by 94
Oostenbrink, C., & van Gunsteren, W. F. (2003) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10558 · Cited by 94
“lated aromatic ring into the pocket that is occupied by the A-ring of the endogenous ligand.(16,17) The protein was”
BackgroundCreating Small-Molecule-Dependent Switches to Modulate Biological Functions
Buskirk, A. R., & Liu, D. R. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.012 · Cited by 94
Xu, Y., Fang, F., Chu, Y., Jones, D., & Jones, G. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03293.x · Cited by 94
Hong, H., Darimont, B. D., Ma, H., Yang, L., Yamamoto, K. R., & Stallcup, M. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3496 · Cited by 88
Defining a conformational ensemble that directs activation of PPARγ
Chrisman, I. M., Nemetchek, M. D., de Vera, I. M. S., Shang, J., Heidari, Z., Long, Y., Reyes-Caballero, H., Galindo‐Murillo, R., Cheatham, T. E., Blayo, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04176-x · Cited by 95
Crosstalk of TGF-β and Estrogen Receptor Signaling in Breast Cancer
Band, A. M., & Laiho, M. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9203-7 · Cited by 93
“Upon ligand binding the conformation of ERα changes and promotes receptor dimerization and high-affinity binding to estrogenresponse element (ERE) [ 42 ].”
BackgroundWiglenda, T., & Gust, R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061106t · Cited by 93
Nuclear receptor full-length architectures: confronting myth and illusion with high resolution
Rastinejad, F., Ollendorff, V., & Polikarpov, I. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.10.011 · Cited by 93
“The binding of different types of ligands to a single NR was subsequently shown for the estrogen receptor (ER) through a series of detailed structure-function studies [9, 10].”
BackgroundBai, Y., & Giguère, V. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0351 · Cited by 93
Structural and Functional Diversity of Estrogen Receptor Ligands
Farooq, A. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150413154841 · Cited by 94
“as determined by Carlquist and co-workers [20], was used as a template (PDBID 1ERE).”
BackgroundMethodInfluentialMechanistic aspects of mineralocorticoid receptor activation
Hellal-Levy, C., Fagart, J., Souque, A., & Rafestin-Oblin, M.-E. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00958.x · Cited by 78
Glucocorticoid Receptor Antagonism by Cyproterone Acetate and RU486
Honer, C., Nam, K., Fink, C. A., Marshall, P., Ksander, G. M., Chatelain, R. E., Cornell, W. D., Steele, R., Schweitzer, R., & Schumacher, C. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.1012 · Cited by 93
“Ligands with transactivation or agonistic function position the AF-2 helix in an active conformation that allows the association of coactivators (Brzozowski et al., 1997).”
BackgroundPrenylation has a compound specific effect on the estrogenicity of naringenin and genistein
Kretzschmar, G., Zierau, O., Wober, J., Tischer, S., Metz, P., & Vollmer, G. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.08.005 · Cited by 92
Biochemical applications of mass spectrometry in pharmaceutical drug discovery
Geoghegan, K. F., & Kelly, M. A. (2004) · Mass Spectrometry Reviews · doi:10.1002/mas.20019 · Cited by 92
Yang, W., & Freedman, L. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.16838 · Cited by 92
Modifying chromatin to permit steroid hormone receptor-dependent transcription
Kinyamu, H. K., & Archer, T. (2003) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2003.09.015 · Cited by 92
Matthews, J. B., & Zacharewski, T. (2000) · Toxicological Sciences · doi:10.1093/toxsci/53.2.326 · Cited by 92
“The human ER a (hERa), considered to be the prototypical ER, was selected as the basis for all comparisons, due to the information available on its ligand-binding characteristics and the structure of the ligand-binding pocket (Brzozowski et al., 1997; Tanenbaum et al., 1998).”
BackgroundInfluentialWang, F., Samudio, I. J., & Safe, S. H. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00379-8 · Cited by 91
Steroid dehydrogenase structures, mechanism of action, and disease
Duax, W. L., Ghosh, D., & Pletnev, V. Z. (2000) · Vitamins and hormones · doi:10.1016/s0083-6729(00)58023-6 · Cited by 91
Modeling correlated main‐chain motions in proteins for flexible molecular recognition
Zavodszky, M. I., Lei, M., Thorpe, M. F., Day, A., & Kuhn, L. A. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20179 · Cited by 91
“The transcriptional activator property of 17 estradiol is determined by its ability to maintain helix 12 of ER in a position where it seals the binding site, an alignment typically prevented by ER antagonists.(60) The dockings provided by SLIDE [Fig.”
Background
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.